POAI vs. HSCS, NAOV, HEPA, CVKD, TBIO, SHPH, KTTA, NH, TENX, and VIRI
Should you be buying Predictive Oncology stock or one of its competitors? The main competitors of Predictive Oncology include Heart Test Laboratories (HSCS), NanoVibronix (NAOV), Hepion Pharmaceuticals (HEPA), Cadrenal Therapeutics (CVKD), Telesis Bio (TBIO), Shuttle Pharmaceuticals (SHPH), Pasithea Therapeutics (KTTA), NantHealth (NH), Tenax Therapeutics (TENX), and Virios Therapeutics (VIRI). These companies are all part of the "medical" sector.
Predictive Oncology (NASDAQ:POAI) and Heart Test Laboratories (NASDAQ:HSCS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, community ranking, profitability, valuation, institutional ownership and risk.
9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 17.2% of Heart Test Laboratories shares are held by institutional investors. 3.4% of Predictive Oncology shares are held by insiders. Comparatively, 2.7% of Heart Test Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Predictive Oncology received 145 more outperform votes than Heart Test Laboratories when rated by MarketBeat users. However, 75.00% of users gave Heart Test Laboratories an outperform vote while only 64.35% of users gave Predictive Oncology an outperform vote.
In the previous week, Predictive Oncology had 2 more articles in the media than Heart Test Laboratories. MarketBeat recorded 6 mentions for Predictive Oncology and 4 mentions for Heart Test Laboratories. Predictive Oncology's average media sentiment score of -0.14 beat Heart Test Laboratories' score of -0.24 indicating that Predictive Oncology is being referred to more favorably in the media.
Heart Test Laboratories has a net margin of 0.00% compared to Predictive Oncology's net margin of -754.13%. Predictive Oncology's return on equity of -151.51% beat Heart Test Laboratories' return on equity.
Predictive Oncology has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500. Comparatively, Heart Test Laboratories has a beta of 3.4, meaning that its stock price is 240% more volatile than the S&P 500.
Heart Test Laboratories has lower revenue, but higher earnings than Predictive Oncology. Predictive Oncology is trading at a lower price-to-earnings ratio than Heart Test Laboratories, indicating that it is currently the more affordable of the two stocks.
Summary
Predictive Oncology beats Heart Test Laboratories on 8 of the 14 factors compared between the two stocks.
Get Predictive Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for POAI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding POAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Predictive Oncology Competitors List
Related Companies and Tools
